143 related articles for article (PubMed ID: 18496498)
1. Farnesyltransferase inhibition in hematologic malignancies: the clinical experience with tipifarnib.
Martinelli G; Iacobucci I; Paolini S; Ottaviani E
Clin Adv Hematol Oncol; 2008 Apr; 6(4):303-10. PubMed ID: 18496498
[TBL] [Abstract][Full Text] [Related]
2. Farnesyltransferase inihibitors in hematologic malignancies.
Harousseau JL
Blood Rev; 2007 Jul; 21(4):173-82. PubMed ID: 17293017
[TBL] [Abstract][Full Text] [Related]
3. Development of the farnesyltransferase inhibitor tipifarnib for therapy of hematologic malignancies.
Karp JE; Lancet JE
Future Oncol; 2005 Dec; 1(6):719-31. PubMed ID: 16556050
[TBL] [Abstract][Full Text] [Related]
4. Clinical activity of tipifarnib in hematologic malignancies.
Jabbour E; Kantarjian H; Cortes J
Expert Opin Investig Drugs; 2007 Mar; 16(3):381-92. PubMed ID: 17302532
[TBL] [Abstract][Full Text] [Related]
5. Role of farnesyltransferase inhibitors in hematologic malignancies.
Santos ES; Rosenblatt JD; Goodman M
Expert Rev Anticancer Ther; 2004 Oct; 4(5):843-56. PubMed ID: 15485318
[TBL] [Abstract][Full Text] [Related]
6. The emerging role of targeted therapy for hematologic malignancies: update on bortezomib and tipifarnib.
Armand JP; Burnett AK; Drach J; Harousseau JL; Löwenberg B; San Miguel J
Oncologist; 2007 Mar; 12(3):281-90. PubMed ID: 17405892
[TBL] [Abstract][Full Text] [Related]
7. Farnesyltransferase inhibitors in myelodysplastic syndrome.
Feldman EJ
Curr Hematol Rep; 2005 May; 4(3):186-90. PubMed ID: 15865870
[TBL] [Abstract][Full Text] [Related]
8. Combining simvastatin with the farnesyltransferase inhibitor tipifarnib results in an enhanced cytotoxic effect in a subset of primary CD34+ acute myeloid leukemia samples.
van der Weide K; de Jonge-Peeters SD; Kuipers F; de Vries EG; Vellenga E
Clin Cancer Res; 2009 May; 15(9):3076-83. PubMed ID: 19383813
[TBL] [Abstract][Full Text] [Related]
9. Farnesyltransferase inhibitor tipifarnib inhibits Rheb prenylation and stabilizes Bax in acute myelogenous leukemia cells.
Ding H; McDonald JS; Yun S; Schneider PA; Peterson KL; Flatten KS; Loegering DA; Oberg AL; Riska SM; Huang S; Sinicrope FA; Adjei AA; Karp JE; Meng XW; Kaufmann SH
Haematologica; 2014 Jan; 99(1):60-9. PubMed ID: 23996484
[TBL] [Abstract][Full Text] [Related]
10. Farnesyltransferase inhibitors in myelodysplastic syndrome.
Feldman EJ
Curr Hematol Malig Rep; 2006 Mar; 1(1):20-4. PubMed ID: 20425327
[TBL] [Abstract][Full Text] [Related]
11. Anti-inflammatory activity in vitro and in vivo of the protein farnesyltransferase inhibitor tipifarnib.
Xue X; Lai KT; Huang JF; Gu Y; Karlsson L; Fourie A
J Pharmacol Exp Ther; 2006 Apr; 317(1):53-60. PubMed ID: 16352705
[TBL] [Abstract][Full Text] [Related]
12. The farnesyl transferase inhibitor, tipifarnib, is a potent inhibitor of the MDR1 gene product, P-glycoprotein, and demonstrates significant cytotoxic synergism against human leukemia cell lines.
Medeiros BC; Landau HJ; Morrow M; Lockerbie RO; Pitts T; Eckhardt SG
Leukemia; 2007 Apr; 21(4):739-46. PubMed ID: 17268526
[TBL] [Abstract][Full Text] [Related]
13. Tipifarnib: farnesyl transferase inhibition at a crossroads.
Mesa RA
Expert Rev Anticancer Ther; 2006 Mar; 6(3):313-9. PubMed ID: 16503848
[TBL] [Abstract][Full Text] [Related]
14. Farnesyltransferase inhibitors: where are we now?
Tsimberidou AM; Chandhasin C; Kurzrock R
Expert Opin Investig Drugs; 2010 Dec; 19(12):1569-80. PubMed ID: 21083522
[TBL] [Abstract][Full Text] [Related]
15. Tipifarnib in acute myeloid leukemia.
Burnett AK; Kell J
Drugs Today (Barc); 2007 Nov; 43(11):795-800. PubMed ID: 18174965
[TBL] [Abstract][Full Text] [Related]
16. In vitro profiling of the sensitivity of pediatric leukemia cells to tipifarnib: identification of T-cell ALL and FAB M5 AML as the most sensitive subsets.
Goemans BF; Zwaan CM; Harlow A; Loonen AH; Gibson BE; Hählen K; Reinhardt D; Creutzig U; Heinrich MC; Kaspers GJ
Blood; 2005 Nov; 106(10):3532-7. PubMed ID: 16051737
[TBL] [Abstract][Full Text] [Related]
17. Active oral regimen for elderly adults with newly diagnosed acute myelogenous leukemia: a preclinical and phase 1 trial of the farnesyltransferase inhibitor tipifarnib (R115777, Zarnestra) combined with etoposide.
Karp JE; Flatten K; Feldman EJ; Greer JM; Loegering DA; Ricklis RM; Morris LE; Ritchie E; Smith BD; Ironside V; Talbott T; Roboz G; Le SB; Meng XW; Schneider PA; Dai NT; Adjei AA; Gore SD; Levis MJ; Wright JJ; Garrett-Mayer E; Kaufmann SH
Blood; 2009 May; 113(20):4841-52. PubMed ID: 19109557
[TBL] [Abstract][Full Text] [Related]
18. Farnesyl transferase inhibition in hematologic malignancies.
Karp JE
J Natl Compr Canc Netw; 2005 Nov; 3 Suppl 1():S37-40. PubMed ID: 16280111
[No Abstract] [Full Text] [Related]
19. Clinical activity of farnesyl transferase inhibitors in hematologic malignancies: possible mechanisms of action.
Jabbour E; Kantarjian H; Cortes J
Leuk Lymphoma; 2004 Nov; 45(11):2187-95. PubMed ID: 15512806
[TBL] [Abstract][Full Text] [Related]
20. Farnesyltransferase inhibitors and their potential role in therapy for myelodysplastic syndromes and acute myeloid leukaemia.
Braun T; Fenaux P
Br J Haematol; 2008 May; 141(5):576-86. PubMed ID: 18410457
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
